Dejana Popovic

Dr. Dejana Popovic


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Progress in Cardiovascular Diseases
Verified
Journal Article
Closed access
DPDejana Popovic
Dejana Popovic
MBMarija Bjelobrk
Marija Bjelobrk
MTMilorad Tesic
Milorad Tesic
SSStefan Seman
Stefan Seman
SJSisitha Jayasinghe
Sisitha Jayasinghe
RARoss Arena
Ross Arena

16 October 2024 in Progress in Cardiovascular Diseases
Verified
Journal Article
Closed access
SSStefan Seman
Stefan Seman
MTMilorad Tesic
Milorad Tesic
MBMarija Babic
Marija Babic
LMLidija Mikic
Lidija Mikic
LVLazar Velicki
Lazar Velicki
DPDejana Popovic
Dejana Popovic

15 December 2025 in Medicina
Verified
Journal Article
Open access
PDF file
MBMarija Babic
Marija Babic
LMLidija Mikic
Lidija Mikic
MRMarko Ristic
Marko Ristic
MTMilorad Tesic
Milorad Tesic
STSnežana Tadić Tadić
Snežana Tadić Tadić
DPDejana Popovic
Dejana Popovic
Multimodal imaging plays a central role in optimizing the evaluation and management of myocardial ischemia by leveraging the complementary strengths of echocardiography, cardiac magnetic resonance imaging (CMR), single photon emission computed tomography (SPECT), positron emission tomography (PET), and invasive coronary angiography (ICA). Noninvasive functional imaging is typically recommended for patients with intermediate to high pre-test probability of coronary artery disease, while coronary computed tomography angiography (CCTA) is preferred for low to intermediate risk. Stress echocardiography is valuable for detecting wall motion abnormalities and is particularly effective in multivessel or left main disease, where perfusion techniques may miss balanced ischemia. CMR offers high spatial resolution and quantitative assessment of myocardial blood flow (MBF), while SPECT and PET quantify ischemic burden, with PET providing superior accuracy for MBF and microvascular disease. ICA remains the gold standard for defining the presence, location, and severity of epicardial coronary stenosis. It is indicated when noninvasive imaging reveals high-risk features, when symptoms are refractory to medical therapy, or when noninvasive results are inconclusive. While ICA offers high spatial resolution, it alone cannot assess the hemodynamic significance of intermediate lesions, nor the coronary microvasculature. Adjunctive invasive hemodynamic and provocative coronary testing (e.g., Fractional Flow Reserve—FFR, invasive Coronary Flow Reserve—CFR, Index of Microcirculatory Resistance—IMR, acetylcholine test) provide essential insights, especially in ischemia with nonobstructive coronary arteries. Given its procedural risks, ICA should be reserved for cases where it will impact management. Intravascular imaging may be used to further characterize lesions. In summary, modality selection should be individualized based on patient characteristics, comorbidities, contraindications, and the need for anatomical versus physiological data. Integrating noninvasive and invasive modalities provides a comprehensive, patient-centered approach to ischemia evaluation.

18 July 2026 in Current Problems in Cardiology
Verified
Journal Article
Closed access
RLRUI feng Liu
RUI feng Liu
RARoss Arena
Ross Arena
ASAldair Darlan Santos-De-Araújo
Aldair Darlan Santos-De-Araújo
ASAudrey Borghi e Silva
Audrey Borghi e Silva
DPDejana Popovic
Dejana Popovic

30 September 2026 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
RLRuifeng Liu
Ruifeng Liu
RARoss Arena
Ross Arena
CLCarl Lavie
Carl Lavie
AAAdelaide M. Arruda-Olson
Adelaide M. Arruda-Olson
DPDejana Popovic
Dejana Popovic
Importance: The development of artificial intelligence (AI) models for atherosclerotic cardiovascular disease (ASCVD) risk prediction has rapidly accelerated. However, despite reports of high predictive accuracy, evidence supporting clinical implementation remains limited. Objective: This study aimed to evaluate the methodological rigor of AI-based ASCVD prediction models and assess whether reported algorithmic discrimination is associated with prespecified reporting and translational-evidence gaps. Data sources and study selection: A systematic search of PubMed, Embase, Web of Science, Scopus, and Cochrane CENTRAL was conducted for original studies published between 1 January 2020 and 27 March 2026. Studies reporting the development or validation of AI and machine learning prognostic models for adult ASCVD outcomes were included. Data extraction and synthesis: Following the PRISMA guidelines, a structured methodological audit was performed. Five binary reporting and translational-evidence gaps were independently extracted: absent calibration assessment, lack of external validation, absent decision-analytic utility evaluation, undefined temporal prediction horizons, and lack of reproducibility or accessibility artifacts. A prespecified minimum evidence proxy for translational evaluation was defined. Main outcomes and measures: The primary outcomes were the cumulative methodological gap burden (range, 0–5) and its association with the primary discrimination metric (area under the receiver operating characteristic curve [AUC] or C-index). Results: Among 101 primary models evaluated, the median discrimination performance was 0.790 (IQR, 0.734–0.833). However, a substantial cumulative gap burden was observed, with only 6.9% of the models meeting the prespecified translational-readiness proxy. Reported discrimination was not associated with methodological completeness; top-quartile models (AUC ≥ 0.833) exhibited high gap burdens at rates comparable to lower-performing models. Reporting and translational-evidence gaps systematically co-occurred, predominantly driven by the simultaneous absence of external validation, calibration assessment, and reproducibility or accessibility artifacts. The use of advanced algorithmic architectures (e.g., deep learning) and multimodal data integration did not independently reduce the reporting gap burden. Conclusion and relevance: In AI-based ASCVD risk prediction, reported algorithmic discrimination is a poor surrogate for clinical readiness. The literature features models with high discrimination but critical methodological deficits. These findings suggest that evaluation frameworks should consider incorporating calibration, external validation, and formal decision-analytic utility assessment alongside discrimination metrics.